Title : LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.

Pub. Date : 2022 Feb

PMID : 34855271






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib epidermal growth factor receptor Mus musculus
2 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib epidermal growth factor receptor Mus musculus
3 With the widely clinical use of third-generation EGFR inhibitor osimertinib for the treatment of EGFR-mutated NSCLC, acquired resistance caused by EGFR C797S tertiary mutation has become a concerned problem. osimertinib epidermal growth factor receptor Mus musculus
4 Meanwhile, LS-106 exhibited comparable kinase inhibitory effect to osimertinib on EGFRL858R/T790M and wild-type EGFR. osimertinib epidermal growth factor receptor Mus musculus